Skip Navigation

European Heart Journal 2001 22(22):2058-2074; doi:10.1053/euhj.2000.2589
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Agema, W. R. P.
Right arrow Articles by Kastelein, J. J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agema, W. R. P.
Right arrow Articles by Kastelein, J. J. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Reviews

Genetic aspects of restenosis after percutaneous coronary interventions;towards more tailored therapy

W. R. P. Agemaa,b, J. W. Jukemaa,b,f1, S. N. Pimstonec and J. J. P. Kasteleind

a Department of Cardiology, Leiden University Medical Center, The Netherlands
b Interuniversity Cardiology Institute of the Netherlands (ICIN), Utrecht, The Netherlands
c Division of Cardiology, University of British Columbia, Vancouver, Canada
d Department of Vascular Medicine, Amsterdam Medical Center, The Netherlands

revised December 19, 2000; accepted December 20, 2000

Key Words: Genetics, restenosis, angioplasty, balloon, stents

f1 Correspondence: J. W. Jukema, MD, PhD, FESC, Leiden University Medical Center, Department of Cardiology, C5-P, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands.

References

  1. Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301:61–68[Abstract]
  2. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316:701–706[Abstract]
  3. Fischman DL, Leon MB, Baim DS. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators [see comments]. N Engl J Med. 1994;331:496–501[Abstract/Free Full Text]
  4. Serruys PW, de Jaegere P, Kiemeneij F. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group [see comments]. N Engl J Med. 1994;331:489–495[Abstract/Free Full Text]
  5. Califf RM. Restenosis: the cost to society. Am Heart J. 1995;130:680–684[CrossRef][Web of Science][Medline]
  6. Popma JJ, De Cesare NB, Pinkerton CA. Quantitative analysis of factors influencing late lumen loss and restenosis after directional coronary atherectomy. Am J Cardiol. 1993;71:552–557[CrossRef][Web of Science][Medline]
  7. Holmes DR Jr., Vlietstra RE, Smith HC. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. 1984;53:77C–81C[CrossRef][Medline]
  8. Weintraub WS, Kosinski AS, Brown CL III, King SB III. Can restenosis after coronary angioplasty be predicted from clinical variables? J Am Coll Cardiol. 1993;21:6–14[Abstract]
  9. Sirnes PA, Molstad P, Myreng Y, Golf S. Predictors for restenosis after angioplasty of chronic coronary occlusions. Int J Cardiol. 1998;67:111–118[CrossRef][Web of Science][Medline]
  10. Rensing BJ, Hermans WR, Vos J. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group. Circulation. 1993;88:975–985[Abstract/Free Full Text]
  11. Lambert M, Bonan R, Cote G. Multiple coronary angioplasty: a model to discriminate systemic and procedural factors related to restenosis. J Am Coll Cardiol. 1988;12:310–314[Abstract]
  12. Bourassa MG, Lesperance J, Eastwood C. Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1991;18:368–376[Abstract]
  13. Kastrati A, Schomig A, Elezi S. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30:1428–1436[Abstract]
  14. Halon DA, Merdler A, Shefer A, Flugelman MY, Lewis BS. Identifying patients at high risk for restenosis after percutaneous transluminal coronary angioplasty for unstable angina pectoris. Am J Cardiol. 1989;64:289–293[CrossRef][Web of Science][Medline]
  15. Hirshfeld JW Jr., Schwartz JS, Jugo R. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART Investigators. J Am Coll Cardiol. 1991;18:647–656[Abstract]
  16. Kotamaki M, Laustiola K, Syvanne M, Heikkila J. Influence of continued smoking and some biological risk factors on restenosis after percutaneous transluminal coronary angioplasty. J Intern Med. 1996;240:293–301[CrossRef][Web of Science][Medline]
  17. Hermans WR, Rensing BJ, Foley DP. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. J Cardiovasc Pharmacol. 1993;22:S45–S57[Medline]
  18. Ellis SG, Shaw RE, Gershony G. Risk factors, time course and treatment effect for restenosis after successful percutaneous transluminal coronary angioplasty of chronic total occlusion. Am J Cardiol. 1989;63:897–901[CrossRef][Web of Science][Medline]
  19. Umans VA, Robert A, Foley D. Clinical, histologic and quantitative angiographic predictors of restenosis after directional coronary atherectomy: a multivariate analysis of the renarrowing process and late outcome. J Am Coll Cardiol. 1994;23:49–58[Abstract]
  20. Serruys PW, Kay IP, Disco C, Deshpande NV, de Feyter PJ. Periprocedural quantitative coronary angiography after Palmaz—Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries. J Am Coll Cardiol. 1999;34:1067–1074[Abstract/Free Full Text]
  21. Mintz GS, Popma JJ, Pichard AD. Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization. J Am Coll Cardiol. 1996;27:1678–1687[Abstract]
  22. Buffon A, Liuzzo G, Biasucci LM. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999;34:1512–1521[Abstract/Free Full Text]
  23. Hoffmann R, Mintz GS, Kent KM. Serial intravascular ultrasound predictors of restenosis at the margins of Palmaz—Schatz stents. Am J Cardiol. 1997;79:951–953[CrossRef][Web of Science][Medline]
  24. Bauters C, Lablanche JM, McFadden EP, Hamon M, Bertrand ME. Relation of coronary angioscopic findings at coronary angioplasty to angiographic restenosis. Circulation. 1995;92:2473–2479[Abstract/Free Full Text]
  25. Itoh A, Miyazaki S, Nonogi H, Daikoku S, Haze K. Angioscopic prediction of successful dilatation and of restenosis in percutaneous transluminal coronary angioplasty. Significance of yellow plaque. Circulation. 1995;91:1389–1396[Abstract/Free Full Text]
  26. Escaned J, Goicolea J, Alfonso F. Propensity and mechanisms of restenosis in different coronary stent designs: complementary value of the analysis of the luminal gain-loss relationship. J Am Coll Cardiol. 1999;34:1490–1497[Abstract/Free Full Text]
  27. Goel PK, Shahi M, Agarwal AK, Srivastava S, Seth PK. Platelet aggregability and occurrence of restenosis following coronary angioplasty. Int J Cardiol. 1997;60:227–231[CrossRef][Web of Science][Medline]
  28. Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J. 1997;133:387–392[CrossRef][Web of Science][Medline]
  29. Rabbani LE, Edelman ER, Ganz P, Selwyn AP, Loscalzo J, Bittl JA. Relation of restenosis after excimer laser angioplasty to fasting insulin levels. Am J Cardiol. 1994;73:323–327[CrossRef][Web of Science][Medline]
  30. Osanai H, Kanayama H, Miyazaki Y, Fukushima A, Shinoda M, Ito T. Usefulness of enhanced insulin secretion during an oral glucose tolerance test as a predictor of restenosis after direct percutaneous transluminal coronary angioplasty during acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol. 1998;81:698–701[CrossRef][Web of Science][Medline]
  31. Yamamoto H, Imazu M, Yamabe T, Ueda H, Hattori Y, Yamakido M. Risk factors for restenosis after percutaneous transluminal coronary angioplasty: role of lipoprotein (a). Am Heart J. 1995;130:1168–1173[CrossRef][Web of Science][Medline]
  32. Zhou YF, Leon MB, Waclawiw MA. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy [see comments]. N Engl J Med. 1996;335:624–630[Abstract/Free Full Text]
  33. Manegold C, Alwazzeh M, Jablonowski H. Prior cytomegalovirus infection and the risk of restenosis after percutaneous transluminal coronary balloon angioplasty [see comments]. Circulation. 1999;99:1290–1294[Abstract/Free Full Text]
  34. Nebert DW. Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics. 2000;10:279–290[CrossRef][Web of Science][Medline]
  35. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet. 2000;355:1358–1361[CrossRef][Web of Science][Medline]
  36. MacLeod DC, Strauss BH, de Jong M. Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol. 1994;23:59–65[Abstract]
  37. Bauters C, Meurice T, Hamon M, McFadden E, Lablanche JM, Bertrand ME. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc Res. 1996;31:835–846[CrossRef][Web of Science][Medline]
  38. Schwartz SM, deBlois D, O'Brien ER. The intima. Soil for atherosclerosis and restenosis. Circ Res. 1995;77:445–465[Free Full Text]
  39. Thyberg J, Hedin U, Sjolund M, Palmberg L, Bottger BA. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis. 1990;10:966–990[Free Full Text]
  40. Perlman H, Maillard L, Krasinski K, Walsh K. Evidence for the Rapid Onset of Apoptosis in Medial Smooth Muscle Cells After Balloon Injury. Circulation. 1997;95:981–987[Abstract/Free Full Text]
  41. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med. 1998;4:1287–1292[CrossRef][Web of Science][Medline]
  42. Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res. 2000;87:184–188[Free Full Text]
  43. Edelman ER, Simons M, Sirois MG, Rosenberg RD. c-myc in vasculoproliferative disease. Circ Res. 1995;76:176–182[Abstract/Free Full Text]
  44. Speir E, Modali R, Huang ES. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis [see comments]. Science. 1994;265:391–394[Abstract/Free Full Text]
  45. Speir E, Huang ES, Modali R. Interaction of human cytomegalovirus with p53: possible role in coronary restenosis. Scand J Infect Dis (Suppl). 1995;99:78–81[Medline]
  46. Tanaka K, Zou JP, Takeda K. Effects of human cytomegalovirus immediate-early proteins on p53mediated apoptosis in coronary artery smooth muscle cells. Circulation. 1999;99:1656–1659[Abstract/Free Full Text]
  47. Matsushita H, Morishita R, Aoki M. Transfection of antisense p53 tumor suppressor gene oligodeoxynucleotides into rat carotid artery results in abnormal growth of vascular smooth muscle cells. Circulation. 2000;101:1447–1452[Abstract/Free Full Text]
  48. Bayes-Genis A, Conover CA, Schwartz RS. The insulinlike growth factor axis: A review of atherosclerosis and restenosis. Circ Res. 2000;86:125–130[Abstract/Free Full Text]
  49. Lehmann KG, Melkert R, Serruys PW. Contributions of frequency distribution analysis to the understanding of coronary restenosis. A reappraisal of the gaussian curve. Circulation. 1996;93:1123–1132[Abstract/Free Full Text]
  50. Mintz GS, Popma JJ, Pichard AD. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94:35–43[Abstract/Free Full Text]
  51. Jukema JW, Bruschke AV, van Boven AJ. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528–2540[Abstract/Free Full Text]
  52. Jukema JW, van Boven AJ, Groenemeijer B. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. Circulation. 1996;94:1913–1918[Abstract/Free Full Text]
  53. Kuivenhoven JA, Jukema JW, Zwinderman AH. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group [see comments]. N Engl J Med. 1998;338:86–93[Abstract/Free Full Text]
  54. de Maat MPM, Jukema JW, Ye S. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol. 1999;83:852–856[CrossRef][Web of Science][Medline]
  55. Nobuyoshi M, Kimura T, Nosaka H. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol. 1988;12:616–623[Abstract]
  56. Serruys PW, Luijten HE, Beatt KJ. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation. 1988;77:361–371[Abstract/Free Full Text]
  57. Grüntzig AR, King SBd, Schlumpf M, Siegenthaler W. Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zürich experience. N Engl J Med. 1987;316:1127–1132[Abstract]
  58. Cambien F, Poirier O, Lecerf L. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction [see comments]. Nature. 1992;359:641–644[CrossRef][Medline]
  59. Rigat B, Hubert C, Alhenc Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–1346[Web of Science][Medline]
  60. Tiret L, Rigat B, Visvikis S. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51:197–205[Web of Science][Medline]
  61. Costerousse O, Allegrini J, Lopez M, Alhenc Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J. 1993;290:33–40[Web of Science][Medline]
  62. Ohishi M, Fujii K, Minamino T, Higaki J, Kamitani A, Rakugi H. A potent genetic risk factor for restenosis [letter]. Nat Genet. 1993;5:324–325[CrossRef][Web of Science][Medline]
  63. Kaski JC, Zhang Y, Calvino R, Vazquez Rodriguez JM, Castro Beiras A, Jeffery S. Angiotensin-converting enzyme insertion/deletion polymorphism and restenosis after coronary angioplasty in unstable angina pectoris. Am J Cardiol. 1996;77:875–877[CrossRef][Web of Science][Medline]
  64. Hamon M, Bauters C, Amant C. Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty. Circulation. 1995;92:296–299[Abstract/Free Full Text]
  65. Samani NJ, O'Toole L, Martin D. Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of and prognosis after myocardial infarction. J Am Coll Cardiol. 1996;28:338–344[Abstract]
  66. Hamon M, Amant C, Bauters C. Dual determination of angiotensin-converting enzyme and angiotensin-II type 1 receptor genotypes as predictors of restenosis after coronary angioplasty. Am J Cardiol. 1998;81:79–81[CrossRef][Web of Science][Medline]
  67. Hamon M, Amant C, Bauters C, Lablanche JM, Bertrand M, Amouyel P. ACE polymorphism, a genetic predictor of occlusion after coronary angioplasty. Am J Cardiol. 1996;78:679–681[CrossRef][Web of Science][Medline]
  68. Gensini F, Battaglini B, Fatini C. [I/D polymorphism of the ACE gene and A1166C of the AT1R gene as risk factors for restenosis after coronary angioplasty] Polimorfismo I/D del gene ACE e A1166C del gene AT1R quali fattori di rischio di restenosi dopo angioplastica coronarica. Minerva Cardioangiol. 1999;47:516[Medline]
  69. Amant C, Bauters C, Bodart JC. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting [see comments]. Circulation. 1997;96:56–60[Abstract/Free Full Text]
  70. Bodart J-C, Amant C, Bauters C. The D allele of the angiotensin I converting enzyme is associated with diffuse in-stent restenosis. J Am Coll Cardiol. 1998;:I-356A
  71. Ribichini F, Steffenino G, Dellavalle A. The pattern (focal/diffuse) of angiographic in-stent restenosis is associated to the I/D polymorphism of the angiotensin converting enzyme gene. J Am Coll Cardiol. 1997;:I-87
  72. Guarda E, Fajuri A, Marchant E. [D/D genotype of the gene for angiotensin converting enzyme as a risk factor for post-stent coronary restenosis (see comments)] El genotipo D/D del gen de la enzima conversiva de la angiotensina como factor de riesgo de reestenosis post-stent coronario. Rev Esp Cardiol. 1999;52:475–480[Web of Science][Medline]
  73. Kastrati A, Koch W, Elezi S. Insertion/deletion polymorphism of the angiotensin-converting enzyme and restenosis after coronary stent placement. J Am Coll Cardiol. 1998;:I-433
  74. Rauchhaus M, Francis DP, Schmidt H, Teichmann W, Glaeser C. Not the ACE gene polymorphism, but the E-selectin gene polymorphism helps to predict restenosis after coronary angioplasty. J Am Coll Cardiol. 1998;:I-393
  75. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet. 1995;11:241–247[CrossRef][Web of Science][Medline]
  76. Rosenthal N, Schwartz RS. In search of perverse polymorphisms. N Engl J Med. 1998;338:122–124[Free Full Text]
  77. Ribichini F, Steffenino G, Dellavalle A. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation. 1998;97:147–154[Abstract/Free Full Text]
  78. Lindpaintner K, Pfeffer MA, Kreutz R. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease [see comments]. N Engl J Med. 1995;332:706–711[Abstract/Free Full Text]
  79. Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation. 1996;94:708–712[Abstract/Free Full Text]
  80. Koch W, Kastrati A, Mehilli J, Bottiger C, von Beckerath N, Schomig A. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. Circulation. 2000;102:197–202[Abstract/Free Full Text]
  81. J Am Coll Cardiol. 1995;25:362–369[Abstract]
  82. Circulation. 1992;86:100–110[Abstract/Free Full Text]
  83. Okamura A, Ohishi M, Rakugi H. Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty. Angiology. 1999;50:811–822[Web of Science][Medline]
  84. Yamabe T, Imazu M, Yamamoto H. Effect of cilazapril on vascular restenosis after percutaneous transluminal coronary angioplasty. Coron Artery Dis. 1995;6:573–579[Web of Science][Medline]
  85. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation. 1998;98:1802–1820[Free Full Text]
  86. Beohar N, Prather A, Yu Q-T. Angiotensin Converting Enzym Genotype DD is a potent risk factor for coronary artery disease and restenosis post percutaneous transluminal angioplasty. J Am Coll Cardiol. 1994;:I-145
  87. Beohar N, Damaraju S, Prather A. Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease. J Investig Med. 1995;43:275–280[Web of Science][Medline]
  88. Carter AM, Ossei Gerning N, Wilson IJ, Grant PJ. Association of the platelet Pl(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bbeta 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation. 1997;96:1424–1431[Abstract/Free Full Text]
  89. Weiss EJ, Bray PF, Tayback M. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis [see comments]. N Engl J Med. 1996;334:1090–1094[Abstract/Free Full Text]
  90. Herrmann SM, Poirier O, Marques Vidal P. The Leu33/Pro polymorphism (PlA1/PlA2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Etude Cas-Temoins de l'Infarctus du Myocarde. Thromb Haemost. 1997;77:1179–1181[Web of Science][Medline]
  91. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis [see comments]. Lancet. 1997;349:385–388[CrossRef][Web of Science][Medline]
  92. Newman PJ, Seligsohn U, Lyman S, Coller BS. The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci USA. 1991;88:3160–3164[Abstract/Free Full Text]
  93. Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature. 1985;318:470–472[CrossRef][Medline]
  94. Jaspers M, Marynen P, Aly MS, Cuppens H, Hilliker C, Cassiman JJ. Localization of the gene encoding the alpha 2 subunit of the human VLA-2 receptor to chromosome 5q23-31. Somat Cell Mol Genet. 1991;17:505–511[CrossRef][Web of Science][Medline]
  95. Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood. 1998;92:2382–2388[Abstract/Free Full Text]
  96. Moshfegh K, Wuillemin WA, Redondo M. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet. 1999;353:351–354[CrossRef][Web of Science][Medline]
  97. Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood. 1999;93:2449–2453[Abstract/Free Full Text]
  98. Croft SA, Hampton KK, Sorrell JA. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br J Haematol. 1999;106:771–776[CrossRef][Web of Science][Medline]
  99. Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis [see comments]. Lancet. 1997;350:1217–1219[CrossRef][Web of Science][Medline]
  100. Laule M, Cascorbi I, Stangl V. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet. 1999;353:708–712[CrossRef][Web of Science][Medline]
  101. Kastrati A, Koch W, Gawaz M. PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement [see comments]. J Am Coll Cardiol. 2000;36:84–89[Abstract/Free Full Text]
  102. Mrozikiewicz PM, Cascorbi I, Ziemer S. Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene. J Am Coll Cardiol. 2000;36:1520–1525[Abstract/Free Full Text]
  103. Mamotte CD, van Bockxmeer FM, Taylor RR. PIa1/a2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol. 1998;82:13–16[Web of Science][Medline]
  104. Kastrati A, Schomig A, Seyfarth M. P1(A) polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation. 1999;99:1005–1010[Abstract/Free Full Text]
  105. Abbate R, Marcucci R, Camacho Vanegas O. Role of platelet glycoprotein PL(A1/A2) polymorphism in restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1998;82:524–525[CrossRef][Web of Science][Medline]
  106. Circulation. 1997;96:1445–1453[Abstract/Free Full Text]
  107. Lancet. 1998;352:87–92[Web of Science][Medline]
  108. Lefkovits J, Ivanhoe RJ, Califf RM. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. Am J Cardiol. 1996;77:1045–1051[CrossRef][Web of Science][Medline]
  109. Tcheng JE, Harrington RA, Kottke-Marchant K. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation. 1995;91:2151–2157[Abstract/Free Full Text]
  110. Topol EJ, Mark DB, Lincoff AM. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting [see comments] [published erratum appears in Lancet 2000 Mar 25; 355(9209): 1104]. Lancet. 1999;354:2019–2024[CrossRef][Web of Science][Medline]
  111. Ellis SG, Effron MB, Gold HK. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 1999;100:799–806[Abstract/Free Full Text]
  112. Bottiger C, Kastrati A, Koch W. Polymorphism of platelet glycoprotein IIb and risk of thrombosis and restenosis after coronary stent placement. Am J Cardiol. 1999;84:987–991[CrossRef][Web of Science][Medline]
  113. von Beckerath N, Koch W, Mehili J, Bottiger C, Schomig A, Kastrati A. Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary stenting. Blood. 2000;95:3297–3301[Abstract/Free Full Text]
  114. Sellers A, Murphy G. Collagenolytic enzymes and their naturally occurring inhibitors. Int Rev Connect Tissue Res. 1981;9:151–190[Web of Science][Medline]
  115. Whitham SE, Murphy G, Angel P. Comparison of human stromelysin and collagenase by cloning and sequence analysis. Biochem J. 1986;240:913–916[Web of Science][Medline]
  116. Matthews BW, Weaver LH, Kester WR. The conformation of thermolysin. J Biol Chem. 1974;249:8030–8044[Abstract/Free Full Text]
  117. Terashima M, Akita H, Kanazawa K, Inoue N, Yamada S, Ito K. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation. 1999;99:2717–2719[Abstract/Free Full Text]
  118. Humphries SE, Luong LA, Talmud PJ. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. Atherosclerosis. 1998;139:49–56[CrossRef][Web of Science][Medline]
  119. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J. 1995;73:209–215[Abstract/Free Full Text]
  120. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996;271:13055–13060[Abstract/Free Full Text]
  121. Amouyel P, Bauters C, Meirhaeghe A, Luong LA, Bertrand M, Humphries SE. The 5A6A polymorphism in the promoter of the stromelysin-1 gene as a risk factor for restenosis (Abstr). Eur Heart J. 1999;20:601
  122. Roth A, Eshchar Y, Keren G. Serum lipids and restenosis after successful percutaneous transluminal coronary angioplasty. Ichilov magnesium Study Group. Am J Cardiol. 1994;73:1154–1158[CrossRef][Web of Science][Medline]
  123. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol. 1996;16:1250–1255[Abstract/Free Full Text]
  124. Damaraju S, Yu QT, Safavi F, Marian AJ. Apolipoprotein epsilon 4 is not a genetic risk factor for coronary artery disease or restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1995;75:1181–1183[CrossRef][Web of Science][Medline]
  125. van Bockxmeer FM, Mamotte CD, Gibbons FR, Taylor RR. Apolipoprotein epsilon 4 homozygosity—a determinant of restenosis after coronary angioplasty. Atherosclerosis. 1994;110:195–202[CrossRef][Web of Science][Medline]
  126. Samani NJ, Martin DS, Brack M. Apolipoprotein E polymorphism does not predict risk of restenosis after coronary angioplasty. Atherosclerosis. 1996;125:209–216[CrossRef][Web of Science][Medline]
  127. Flork L, Jouanel P, Lusson JR. [Influence of alleles of apolipoprotein E on restenosis after coronary angioplasty in women] Influence des alleles de l'apolipoproteine E sur la restenose apres angioplastie coronaire chez la femme. Arch Mal Coeur Vaiss. 1998;91:1475–1479[Web of Science][Medline]
  128. van Beusekom HM, van der Giessen WJ, van Suylen R, Bos E, Bosman FT, Serruys PW. Histology after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation. J Am Coll Cardiol. 1993;21:45–54[Abstract]
  129. Kastrati A, Koch W, Berger PB. Protection against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting (Abstr). J Am Coll Cardiol. 2000;35 [2:326A–326A
  130. van Bockxmeer FM, Mamotte CD, Gibbons FA, Burke V, Taylor RR. Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty. Circulation. 1995;92:2066–2071[Abstract/Free Full Text]
  131. Kibbe MR, Billiar TR, Tzeng E. Gene therapy for restenosis. Circ Res. 2000;86:829–833[Free Full Text]
  132. Lynch CM, Hara PS, Leonard JC, Williams JK, Dean RH, Geary RL. Adeno-associated virus vectors for vascular gene delivery. Circ Res. 1997;80:497–505[Web of Science][Medline]
  133. Leiden JM. Human gene therapy: the good, the bad, and the ugly. Circ Res. 2000;86:923–925[Free Full Text]
  134. Miyatake SI, Yukawa H, Toda H. Inhibition of rat vascular smooth muscle cell proliferation in vitro and in vivo by recombinant replication-competent herpes simplex virus—Editorial Comment. Stroke. 1999;30:2431–243a[Abstract/Free Full Text]
  135. Claudio PP, Fratta L, Farina F. Adenoviral RB2/p130 Gene Transfer Inhibits Smooth Muscle Cell Proliferation and Prevents Restenosis After Angioplasty. Circ Res. 1999;85:1032–1039[Abstract/Free Full Text]
  136. Vatner DE, Kunze DL. Prologue: low-molecular-weight GTPases in the heart and circulation. Am J Physiol. 2000;278:H1733–H1735[Web of Science]
  137. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol (Lond). 2000;522:177–185[Abstract/Free Full Text]
  138. Seasholtz TM, Majumdar M, Kaplan DD, Heller Brown J. Rho and Rho Kinase Mediate Thrombin-Stimulated Vascular Smooth Muscle Cell DNA Synthesis and Migration. Circulation Res. 1999;84:1186–1193[Abstract/Free Full Text]
  139. Eto Y, Shimokawa H, Hiroki J. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol. 2000;278:H1744–H1750[Web of Science]
  140. von Essen R, Ostermaier R, Grube E. Effects of Octreotide Treatment on Restenosis After Coronary Angioplasty: Results of the VERAS Study. Circulation. 1997;96:1482–1487[Abstract/Free Full Text]
  141. Eriksen UH, Amtorp O, Bagger JP. Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am Heart J. 1995;130:1–8[CrossRef][Web of Science][Medline]
  142. Kent KM, Williams DO, Cassagneau D. Double blind, controlled trial of the effect of angiopeptin on coronary restenosis following balloon angioplasty (Abstr). Circulation. 1993;88:I-506
  143. Wang J, Niu W, Witte DP. Overexpression of insulin-like growth factor-binding protein-4 (IGFBP-4) in smooth muscle cells of transgenic mice through a smooth muscle obralphaobl-actin-IGFBP-4 fusion gene induces smooth muscle hypoplasia. Endocrinology. 1998;139:2605–2614[Abstract/Free Full Text]
  144. Thelander L, Reichard P. Reduction of ribonucleotides. Annu Rev Biochem. 1979;48:133–158[CrossRef][Web of Science][Medline]
  145. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 1992;359:67–70[CrossRef][Medline]
  146. Shi Y, Fard A, Galeo A. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation. 1994;90:944–951[Abstract/Free Full Text]
  147. Simons M, Edelman ER, Rosenberg RD. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J Clin Invest. 1994;93:2351–2356[Web of Science][Medline]
  148. Morishita R, Gibbons GH, Ellison KE. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA. 1993;90:8474–8478[Abstract/Free Full Text]
  149. Morishita R, Gibbons GH, Ellison KE. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994;93:1458–1464[Web of Science][Medline]
  150. Indolfi C, Avvedimento EV, Rapacciuolo A. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo [see comments]. Nat Med. 1995;1:541–545[CrossRef][Web of Science][Medline]
  151. Pollman MJ, Hall JL, Mann MJ, Zhang L, Gibbons GH. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med. 1998;4:222–227[CrossRef][Web of Science][Medline]
  152. Morishita R, Sugimoto T, Aoki M. In vivo transfection of cis element decoy' against nuclear factor-kappaB binding site prevents myocardial infarction [see comments]. Nat Med. 1997;3:894–899[CrossRef][Web of Science][Medline]
  153. Morishita R, Gibbons GH, Horiuchi M. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA. 1995;92:5855–5859[Abstract/Free Full Text]
  154. Burgess TL, Fisher EF, Ross SL. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA. 1995;92:4051–4055[Abstract/Free Full Text]
  155. Mann MJ, Whittemore AD, Donaldson MC. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet. 1999;354:1493–1498[CrossRef][Web of Science][Medline]
  156. Morishita R, Gibbons GH, Tomita N. Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation: evidence for tissue angiotensin-converting enzyme function. Arterioscler, Thromb, Vasc Biol. 2000;20:915–922[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Takahashi
Genetic Susceptibility to Restenosis: Role of Bone Marrow Cells and Inflammatory Response
Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1407 - 1408.
[Full Text] [PDF]

Home page
 CirculationHome page
P. S. Monraats, N. M.M. Pires, W. R.P. Agema, A. H. Zwinderman, A. Schepers, M. P.M. de Maat, P. A. Doevendans, R. J. de Winter, R. A. Tio, J. Waltenberger, et al.
Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions
Circulation, October 18, 2005; 112(16): 2417 - 2425.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
W. R.P Agema, P. S Monraats, A. H Zwinderman, R. J de Winter, R. A Tio, P. A.F.M Doevendans, J. Waltenberger, M. P.M de Maat, R. R Frants, D. E Atsma, et al.
Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era
Eur. Heart J., July 1, 2004; 25(13): 1163 - 1170.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
M. V. Podgoreanu and D. A. Schwinn
Genomics and the circulation
Br. J. Anaesth., July 1, 2004; 93(1): 140 - 148.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
L. J Wagenaar, A. J van Boven, A. C van der Wal, G. Amoroso, R. A Tio, C. M van der Loos, A. E Becker, and W. H van Gilst
Differential localisation of the renin-angiotensin system in de-novo lesions and in-stent restenotic lesions in in-vivo human coronary arteries
Cardiovasc Res, October 1, 2003; 59(4): 980 - 987.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
X. Wang and B. Paigen
Comparative Genetics of Atherosclerosis and Restenosis: Exploration With Mouse Models
Arterioscler Thromb Vasc Biol, June 1, 2002; 22(6): 884 - 886.
[Full Text] [PDF]

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Agema, W. R. P.
Right arrow Articles by Kastelein, J. J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agema, W. R. P.
Right arrow Articles by Kastelein, J. J. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?